ICT, Takeda, and PACT Pharma Report Clinical Data in Solid Tumors; SITC 2022 Final Analysis
Here is a brief preview of this blast: SITC 2022 Final Analysis: Innovative Cellular Therapeutics (ICT), Takeda, and PACT Pharma presented clinical results from their T cell therapies in solid tumors. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below: